65G:F:F-NEXTCELL PHARMA AB (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.102

Change

0.00 (0.00)%

Market Cap

USD 5.61M

Volume

350.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOVA:F Novo Nordisk A/S

+4.50 (+3.41%)

USD 587.96B
VX1:F Vertex Pharmaceuticals Incorpo..

+2.65 (+0.60%)

USD 115.53B
RGO:F Regeneron Pharmaceuticals Inc

+1.40 (+0.14%)

USD 106.36B
CSJA:F CSL LTD SPON.ADR 2

+0.50 (+0.56%)

USD 88.75B
CSJ:F CSL Limited

+0.86 (+0.48%)

USD 88.09B
0QF:F Moderna Inc

+1.96 (+1.56%)

USD 48.70B
UNC:F UCB SA

-1.45 (-1.04%)

USD 26.16B
UNC0:F UCB S.A. UNSP.ADR 1/2

N/A

USD 26.00B
1AE:F Argen-X

+4.40 (+1.09%)

USD 25.27B
1AEA:F argenx SE

+44.00 (+11.70%)

USD 25.06B

ETFs Containing 65G:F

IQQ5:F iShares II Public Limited.. 6.30 % 0.00 %

N/A

USD 0.10B
IQQ5:XETRA iShares MSCI Turkey UCITS.. 6.30 % 0.00 %

-0.24 (0%)

USD 0.10B
ITKY:LSE iShares II Public Limited.. 6.21 % 0.00 %

-20.50 (0%)

USD 0.13B
IDTK:LSE iShares MSCI Turkey UCITS 6.21 % 0.00 %

-0.30 (0%)

USD 0.13B
HTRY:SW 5.33 % 0.00 %

N/A

N/A
TUR iShares MSCI Turkey ETF 4.58 % 0.59 %

-0.28 (0%)

USD 0.27B
FEM:LSE First Trust Emerging Mark.. 1.51 % 0.00 %

-14.50 (0%)

USD 0.01B
FEMU:LSE First Trust Global Funds .. 1.51 % 0.00 %

-0.22 (0%)

USD 0.01B
FEM First Trust Emerging Mark.. 1.49 % 0.80 %

-0.06 (0%)

USD 0.45B
HTRY:LSE 0.00 % 0.00 %

N/A

N/A
HTRD:LSE 0.00 % 0.00 %

N/A

N/A
HTR:PA 0.00 % 0.00 %

N/A

N/A
H4ZK:F 0.00 % 0.00 %

N/A

N/A
H4ZK:XETRA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -48.61% 14% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.61% 14% F 6% D-
Trailing 12 Months  
Capital Gain -71.02% 15% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -71.02% 15% F 6% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -20.08% 20% F 8% B-
Dividend Return -20.08% 20% F 7% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 31.69% 51% F 37% F
Risk Adjusted Return -63.39% 21% F 10% F
Market Capitalization 5.61M 12% F 8% B-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.